I've got a question.
What's this all about?
Cynata Therapeutics (ASX:CYP) continues MEND trial on DSMB recommendation – The Market Herald
Where's the money?
Ha ha ha. Keystone cops.
As a non-shareholder, I probably just don't understand.
“We thank the members of the independent DSMB for completing this important review,” Dr Kelly said.
“The DSMB’s positive recommendation is an important milestone, which enables us to continue patient enrolment in the MEND clinical trial and advance toward our goal of completing the trial later this year.”
In two months. Right-o.
Everything is happening before the end of 2022.
(20min delay)